Preventing familial amyotrophic lateral sclerosis: Is a clinical trial feasible?

Journal of the Neurological Sciences

Volumn 251, Issue 1-2, 2006, Pages 3-9

  Benatar, Michael ^a   Polak, Meraida ^a   Kaplan, Samantha ^a   Glass, Jonathan ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trial; Epidemiology; fALS; Genetic risk

Indexed keywords

ADOLESCENT; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ATTITUDE TO HEALTH; CHILD; CLINICAL RESEARCH; CONTROLLED STUDY; FEASIBILITY STUDY; GENETIC RISK; HIGH RISK POPULATION; HUMAN; INFANT; INTERVIEW; NEWBORN; ONSET AGE; PEDIGREE; PRIORITY JOURNAL; SAMPLE SIZE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE OF ONSET; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; ATTITUDE TO HEALTH; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; FAMILY HEALTH; FEASIBILITY STUDIES; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; RISK; SUPEROXIDE DISMUTASE;

EID: 33751228383     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.05.069     Document Type: Article

References (21)

1. Gurney M., Cutting F., and Zhai P. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 39 (1996) 147-157
2. Desnuelle C., Dib M., Garrel C., et al. A double-blind, placebo-controlled randomized clinical trial of a-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord 2 (2001) 9-18
3. Klivenyi P., Ferrante R., and Matthews R. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 5 (1999) 347-350
4. Shefner J., Cudkowicz M., Schoenfeld D., et al. A clinical trial of creatine in ALS. Neurology 63 (2004) 1656-1661
5. Drachman D.B., Frank K., Dykes-Hoberg M., et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 52 (2002) 771-778
6. Gurney M., Pu H., and Chiu A. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264 (1994) 1772-1775
7. Mulder D.W. The clinical syndrome of amyotrophic lateral sclerosis. Staff Meet Mayo Clin 32 (1957) 427-436
8. Mulder D.W., Kurland L.T., Offord K.P., et al. Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology 36 (1986) 511-517
9. Li T.M., Alberman E., and Swash M. Comparison of sporadic and familial disease amongst 580 cases of motor neuron disease. J Neurol Neurosurg Psychiatry 51 (1988) 778-784
10. Castro-Costa C.M., Oria R.B., Vale O.C., et al. Motor neuron diseases in the university hospital of Fortaleza (Northeastern Brazil): a clinico-demographic analysis of 87 cases. Arq Neuro-Psiquiatr 58 (2000) 986-989
11. Thijs V., Peeters E., Theys P., et al. Demographic characteristics and prognosis in a Flemish amyotrophic lateral sclerosis population. Acta Neurol Belg 100 (2000) 84-90
12. Andersen P., Nilsson P., Keranen M., et al. Phenotypic heterogeneity in motor neuron disease patients with CuZn superoxide dismutase mutations in Scandinavia. Brain 120 (1997) 1723-1737
13. Cudkowicz M., McKenna-Yasek D., et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 41 (1997) 210-221
14. Orrell R., Bahgood J., Gardiner I., et al. Clinical and functional investigation of 10 missense mutations and a novel frameshift insertion mutation of the gene for copper-zinc superoxide dismutase in UK families with amyotrophic lateral sclerosis. Neurology 48 (1997) 746-751
15. Siddique T., Figlewicz D., Pericak-Vance M., et al. Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. New Engl J Med 324 (1991) 1381-1384
16. Emery A.E. Familial motor neuron diseases. In: Rowland L.P. (Ed). Human Motor Neuron Diseases (1982), Raven Press, New York 139-145
17. Annegers J.F., Appel S., Lee R.-J., et al. Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985-1988. Arch Neurol 48 (1991) 589-593
18. Kurland L.T. Descriptive epidemiology of selected neurologic and myopathic disorders with particular reference to a survey in Rochester, Minnesota. J Chronic Dis 8 (1958) 378-418
19. Fanos J.H., Gelinas D.F., and Millert R.G. "You have shown me my end": attitudes towards presymptomatic testing for familial amyotrophic lateral sclerosis. Am J Med Genet 129A (2004) 248-253
20. Zhang W., Narayanan M., and Friedlander R.M. Additive neuroprotective effects of minocycline in a mouse model of ALS. Ann Neurol 53 (2003) 267-270
21. Ascherio A., Weisskopf M., O'reilly E., et al. Vitamin E intake and risk of amyotrophic lateral sclerosis. Ann Neurol 57 (2005) 104-110